| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
SKL2001 (SKL-2001) is a novel and potent agonist of Wnt/β-catenin signaling pathway with antitumor activity. SKL2001 can disrupt the Axin/β-catenin interaction, thus stabilizing intracellular β-catenin.
| ln Vitro |
While it has no effect on NF-κB, p53 reporter gene activity, or GSK-3β activity, SKL2001 is an agonist of the Wnt/β-catenin pathway and can also upregulate the expression of Axin2, a downstream target of the Wnt/β-catenin pathway. By stimulating the Wnt/β-catenin pathway, SKL2001 causes osteoblast differentiation (20 and 40 μM) and inhibits preadipocyte differentiation (5, 10 and 30 μM). In 3T3-L1 cells, SKL2001 (5, 10 and 30 μM) stabilizes intracellular β-catenin [1]. HCT116 spheroids are considerably inhibited from proliferating, regardless of cytotoxicity, by SKL2001 (40 μM), and this inhibition is reversible; SKL2001 leads HCT116 spheroids to enter the cell cycle arrest state. E-cadherin expression and round spheroid formation are enhanced by SKL2001 (40 μM) [2].
|
|---|---|
| References |
|
| Molecular Formula |
C14H14N4O3
|
|---|---|
| Molecular Weight |
286.291
|
| Exact Mass |
286.106
|
| Elemental Analysis |
C, 58.74; H, 4.93; N, 19.57; O, 16.77
|
| CAS # |
909089-13-0
|
| PubChem CID |
16003447
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
595.7±50.0 °C at 760 mmHg
|
| Flash Point |
314.1±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.655
|
| LogP |
0.37
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
21
|
| Complexity |
355
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C=C(C2=CC=CO2)ON=1)NCCCN1C=CN=C1
|
| InChi Key |
PQXINDBPUDNMPE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H14N4O3/c19-14(16-4-2-6-18-7-5-15-10-18)11-9-13(21-17-11)12-3-1-8-20-12/h1,3,5,7-10H,2,4,6H2,(H,16,19)
|
| Chemical Name |
5-(Furan-2-yl)-N-(3-imidazol-1-ylpropyl)-1,2-oxazole-3-carboxamide
|
| Synonyms |
SKL2001Wnt Agonist II SKL-2001 SKL 2001
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 96.66 mg/mL (~337.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4930 mL | 17.4648 mL | 34.9296 mL | |
| 5 mM | 0.6986 mL | 3.4930 mL | 6.9859 mL | |
| 10 mM | 0.3493 mL | 1.7465 mL | 3.4930 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
